Pulse Tracker to Inform the Launch of New HIV Drugs in a Competitive Market

The client looked to ThinkGen to help identify the appropriate patient and use case to build HCP experience with these two HIV brands. As with any launch, monitoring adoption and use is critical, especially in the HIV space, as there are already many effective options available to treat HIV. There were competitive advantages to the client’s two drugs, particularly with growing clinical experience reports of a favorable tolerability profile vs. existing integrase STRs.

Additionally, the client wanted to monitor and more deeply understand HCP interaction with pharmaceutical reps, their beliefs about these two new drugs, and how the drugs would be used. Specifically, the client sought for ThinkGen to determine if the HCPs view their two drugs as a viable switch option from integrase inhibitors, and which of the two drugs they would prefer and why. The client also wanted to know if the HCPs would ever use either of their drugs as a first line treatment instead of the leading integrase inhibitor.

Fill out the form to read our case study

What We Value

uHaf8W.tif

Integrity & Passion

We care and it shows. Unwavering customer focus & commitment to excellence are intrinsic to ThinkGen.
stTQom.tif

Mutual Respect

We value empathy and active listening, and foster a collaborative environment that supports and celebrates the diverse voices of our employees.
BZICZL.tif

Intellectual Curiosity

We’re always willing to try new things and aren’t afraid to fail, because it takes perseverance to forge new paths.
5wPp0A.tif

Continuous Innovation

We challenge ourselves daily to rethink and reimagine solutions for the obstacles our clients face.
ThinkGen is a corporate sponsor of the Healthcare Businesswomen’s Association (HBA)
Copyright © Gen., LLC 2022. All Rights Reserved